Center-Authored Papers

Filters: Author is Lin, Yukang  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
Pagel JM, Kenoyer AL, Bäck T, Hamlin DK, Wilbur SD, Fisher DR, Park SI, Frayo S, Axtman A, Orgun N et al..  2011.  Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model.. Blood. 118(3):703-11. Abstract
James SE, Orgun NN, Tedder TF, Shlomchik MJ, Jensen MC, Lin Y, Greenberg PD, Press OW.  2009.  Antibody-mediated B-cell depletion before adoptive immunotherapy with T cells expressing CD20-specific chimeric T-cell receptors facilitates eradication of leukemia in immunocompetent mice.. Blood. 114(27):5454-63. Abstract
James SE, Greenberg PD, Jensen MC, Lin Y, Wang J, Till BG, Raubitschek AA, Forman SJ, Press OW.  2008.  Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane.. Journal of immunology (Baltimore, Md. : 1950). 180(10):7028-38. Abstract
Green DJ, Shadman M, Jones JC, Frayo SL, Kenoyer AL, Hylarides MD, Hamlin DK, Wilbur SD, Balkan ER, Lin Y et al..  2015.  Astatine-211 conjugated to an anti-CD20 monoclonal antibody eradicates disseminated B-cell lymphoma in a mouse model.. Blood. 125(13):2111-9. Abstract
C
Till BG, Jensen MC, Wang J, Qian X, Gopal AK, Maloney DG, Lindgren CG, Lin Y, Pagel JM, Budde LE et al..  2012.  CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results.. Blood. 119(17):3940-50. Abstract
Budde LE, Berger C, Lin Y, Wang J, Lin X, Frayo SE, Brouns SA, Spencer DM, Till BG, Jensen MC et al..  2013.  Combining a CD20 Chimeric Antigen Receptor and an Inducible Caspase 9 Suicide Switch to Improve the Efficacy and Safety of T Cell Adoptive Immunotherapy for Lymphoma.. PloS one. 8(12):e82742. Abstract
Green DJ, Frayo SL, Lin Y, Hamlin DK, Fisher DR, Frost SHL, Kenoyer AL, Hylarides MD, Gopal AK, Gooley TA et al..  2016.  Comparative analysis of bispecific antibody and streptavidin-targeted radioimmunotherapy for B cell cancers.. Cancer research. Abstract
Pagel JM, Orgun N, Hamlin DK, Wilbur SD, Gooley TA, Gopal AK, Park SI, Green DJ, Lin Y, Press OW.  2009.  A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations.. Blood. 113(20):4903-13. Abstract
Pantelias A, Pagel JM, Hedin N, Saganic L, Wilbur S, Hamlin DK, Wilbur SD, Lin Y, Stone D, Axworthy D et al..  2007.  Comparative biodistributions of pretargeted radioimmunoconjugates targeting CD20, CD22, and DR molecules on human B-cell lymphomas.. Blood. 109(11):4980-7. Abstract
Frost SHL, Frayo SL, Miller BW, Orozco JJ, Booth GC, Hylarides MD, Lin Y, Green DJ, Gopal AK, Pagel JM et al..  2015.  Comparative efficacy of 177Lu and 90Y for anti-CD20 pretargeted radioimmunotherapy in murine lymphoma xenograft models.. PloS one. 10(3):e0120561. Abstract
Pagel JM, Lin Y, Hedin N, Pantelias A, Axworthy D, Stone D, Hamlin DK, Wilbur SD, Press OW.  2006.  Comparison of a tetravalent single-chain antibody-streptavidin fusion protein and an antibody-streptavidin chemical conjugate for pretargeted anti-CD20 radioimmunotherapy of B-cell lymphomas.. Blood. 108(1):328-36. Abstract
Park SI, Shenoi J, Pagel JM, Hamlin DK, Wilbur SD, Orgun N, Kenoyer AL, Frayo S, Axtman A, Bäck T et al..  2010.  Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease.. Blood. 116(20):4231-9. Abstract
D
Wilbur SD, Park SI, Chyan M-K, Wan F, Hamlin DK, Shenoi J, Lin Y, Wilbur SM, Buchegger F, Pantelias A et al..  2010.  Design and synthesis of bis-biotin-containing reagents for applications utilizing monoclonal antibody-based pretargeting systems with streptavidin mutants.. Bioconjugate chemistry. 21(7):1225-38. Abstract
E
Pagel JM, Hedin N, Drouet L, Wood BL, Pantelias A, Lin Y, Hamlin DK, Wilbur SD, Gopal AK, Green DJ et al..  2008.  Eradication of disseminated leukemia in a syngeneic murine leukemia model using pretargeted anti-CD45 radioimmunotherapy.. Blood. 111(4):2261-8. Abstract
Pagel JM, Pantelias A, Hedin N, Wilbur S, Saganic L, Lin Y, Axworthy D, Hamlin DK, Wilbur SD, Gopal AK et al..  2007.  Evaluation of CD20, CD22, and HLA-DR targeting for radioimmunotherapy of B-cell lymphomas.. Cancer research. 67(12):5921-8. Abstract
Nemecek ER, Green DJ, Fisher DR, Pagel JM, Lin Y, Gopal AK, Durack LD, Rajendran JG, Wilbur SD, Nilsson R et al..  2008.  Extracorporeal adsorption therapy: a method to improve targeted radiation delivered by radiometal-labeled monoclonal antibodies.. Cancer biotherapy & radiopharmaceuticals. 23(2):181-91. Abstract
G
Lin Y, Pagel JM, Axworthy D, Pantelias A, Hedin N, Press OW.  2006.  A genetically engineered anti-CD45 single-chain antibody-streptavidin fusion protein for pretargeted radioimmunotherapy of hematologic malignancies.. Cancer research. 66(7):3884-92. Abstract
M
James SE, Greenberg PD, Jensen MC, Lin Y, Wang J, Budde LE, Till BG, Raubitschek AA, Forman SJ, Press OW.  2010.  Mathematical modeling of chimeric TCR triggering predicts the magnitude of target lysis and its impairment by TCR downmodulation.. Journal of immunology (Baltimore, Md. : 1950). 184(8):4284-94. Abstract
O
Wang J, Jensen M, Lin Y, Sui X, Chen E, Lindgren CG, Till B, Raubitschek A, Forman SJ, Qian X et al..  2007.  Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains.. Human gene therapy. 18(8):712-25. Abstract
P
Green DJ, Orgun NN, Jones JC, Hylarides MD, Pagel JM, Hamlin DK, Wilbur DS, Lin Y, Fisher DR, Kenoyer AL et al..  2014.  A Preclinical Model of CD38-Pretargeted Radioimmunotherapy for Plasma Cell Malignancies.. Cancer research. 74(4):1179-89. Abstract
Green DJ, Pagel JM, Pantelias A, Hedin N, Lin Y, Wilbur SD, Gopal A, Hamlin DK, Press OW.  2007.  Pretargeted radioimmunotherapy for B-cell lymphomas.. Clinical cancer research : an official journal of the American Association for Cancer Research. 13(18 Pt 2):5598s-5603s. Abstract
Pagel JM, Matthews DC, Kenoyer A, Hamlin DK, Wilbur DS, Fisher DR, Gopal AK, Lin Y, Saganic L, Appelbaum FR et al..  2009.  Pretargeted radioimmunotherapy using anti-CD45 monoclonal antibodies to deliver radiation to murine hematolymphoid tissues and human myeloid leukemia.. Cancer research. 69(1):185-92. Abstract
Park SI, Shenoi J, Frayo SM, Hamlin DK, Lin Y, Wilbur SD, Stayton PS, Orgun N, Hylarides M, Buchegger F et al..  2011.  Pretargeted radioimmunotherapy using genetically engineered antibody-streptavidin fusion proteins for treatment of non-hodgkin lymphoma.. Clinical cancer research : an official journal of the American Association for Cancer Research. 17(23):7373-82. Abstract
Green DJ, Pagel JM, Nemecek ER, Lin Y, Kenoyer A, Pantelias A, Hamlin DK, Wilbur SD, Fisher DR, Rajendran JG et al..  2009.  Pretargeting CD45 enhances the selective delivery of radiation to hematolymphoid tissues in nonhuman primates.. Blood. 114(6):1226-35. Abstract
Yang Q, Parker CL, Lin Y, Press OW, Park SI, Lai SK.  2017.  Pretargeting with bispecific fusion proteins facilitates delivery of nanoparticles to tumor cells with distinct surface antigens.. Journal of controlled release : official journal of the Controlled Release Society. Abstract